Daiwa Securities Group Inc. decreased its stake in shares of Danaher Co. (NYSE:DHR) by 1.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 66,960 shares of the conglomerate’s stock after selling 683 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Danaher were worth $9,671,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the company. Dorsey Wright & Associates raised its stake in shares of Danaher by 1.5% during the second quarter. Dorsey Wright & Associates now owns 32,512 shares of the conglomerate’s stock worth $4,647,000 after buying an additional 467 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Danaher by 255.9% during the second quarter. WINTON GROUP Ltd now owns 16,441 shares of the conglomerate’s stock worth $2,350,000 after buying an additional 11,821 shares during the last quarter. KAMES CAPITAL plc bought a new stake in shares of Danaher during the second quarter worth approximately $2,868,000. Empirical Finance LLC bought a new stake in shares of Danaher during the second quarter worth approximately $212,000. Finally, Calton & Associates Inc. bought a new stake in shares of Danaher during the second quarter worth approximately $458,000. Institutional investors own 78.30% of the company’s stock.
DHR has been the subject of a number of recent research reports. Robert W. Baird boosted their price target on shares of Danaher from $131.00 to $148.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Credit Suisse Group reissued an “outperform” rating and set a $151.00 price target on shares of Danaher in a research note on Monday, October 14th. Royal Bank of Canada set a $134.00 price target on shares of Danaher and gave the stock a “hold” rating in a research note on Friday, July 19th. Wolfe Research set a $154.00 price target on shares of Danaher and gave the stock a “buy” rating in a research note on Friday, October 25th. Finally, ValuEngine downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $145.86.
NYSE:DHR traded up $0.75 during trading hours on Friday, hitting $135.25. The stock had a trading volume of 114,090 shares, compared to its average volume of 2,087,691. Danaher Co. has a one year low of $94.59 and a one year high of $147.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.09 and a current ratio of 3.43. The company has a market cap of $95.87 billion, a price-to-earnings ratio of 29.92, a P/E/G ratio of 2.24 and a beta of 0.92. The business’s 50 day moving average is $139.29 and its 200-day moving average is $138.24.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, October 24th. The conglomerate reported $1.16 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.15 by $0.01. The firm had revenue of $5.04 billion during the quarter, compared to the consensus estimate of $5.02 billion. Danaher had a net margin of 12.13% and a return on equity of 11.42%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.10 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 4.76 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend was Thursday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 15.04%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: How to start trading in the forex market?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.